BioSpace News Archive

NEW HAVEN, Conn., Feb. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the BIO CEO & Investor Conference being held February 10 – 11, 2020 in New York City. Presentation De

- Vaccine Was Most Effective in Stage IV Melanoma; 73 Percent of Patients Who Completed the Primary Vaccine Series Were Disease-Free at 24 Months - - Results Reflect Synergistic Anti-Tumor Effect When Vaccine is Combined with Checkpoint Inhibitors -

Afya Limited, or Afya (Nasdaq: AFYA), today announced the pricing of a follow-on public offering of 12,426,740 Class A common shares at a public offering price of $27.50 per share, consisting of 3,019,928 Class A common shares offered by Afya, and 9,406,812 Class A common shares offered by certain selling shareholders of Afya (the “Selling Shareholders”),

Pharvaris B.V., a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other B2-receptor-mediated indications, has appointed Peng Lu, M.D., Ph.D., to the newly-created position of Chief Medical Officer, a role in which she will oversee global clinical development and regulatory strategies for Pharvaris.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the second quarter of f

CINCINNATI, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019. First Quarter Fiscal 2020 Highlights: Diagnostics segment delivered nearly $35 million in revenues; fourth consecutive quarter above $33 million, signaling continued stabilization of this business; Positive customer feedback for our revogene™ molecular diagnostics system continues to build; Diagnostics segment new product

SAN DIEGO, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, announced today that it has transferred its Nasdaq listing to the Nasdaq Capital Market and is in compliance with the stockholders’ equity standard to remain listed on the Nasdaq Capital Market. About TRACON TRACON develops targeted therapies for cancer and ophthalmic diseas

Allied Corp. (“Allied”) (OTCQB: ALID) – an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues – is pleased to announce the signing of a non-binding letter of intent between Hollister Biosciences Inc. (“Hollister”) and Allied Corp. affiliate Tactical Relief, LLC (“Tactical Relief”) with respect to the joint development and introduction of TACTICAL RELIEF™ branded products to the California market.

Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced new appointments to its leadership team. Wendy Arnold has joined the company as Chief People Officer, and Lisa Geller, Ph.D., J.D., is the company’s new Head of Intellectual Property.

Feb. 7, 2020 13:00 UTC Activist Attempts to Prevent Enzo Shareholders from Exercising Their Right to Vote on Board Expansion Proposal NEW YORK--( BUSINESS WIRE )-- Enzo Biochem, Inc. (NYSE:ENZ) (the “Company”) today disclosed that Harbert Discovery Fund, LP (“Harbert”) filed a lawsuit against the Company and the members of its board of directors (“Board”) in the U.S. District Court for the Southern District of New York. Enzo commented as follows: “We are disappoin